Eisai's Eribulin (Halaven(R)) Receives Swissmedic Approval For Use In Locally Advance

[News]

Eribulin (Halaven(R)) is today approved for use in Switzerland by Swissmedic, the Swiss Agency for Therapeutic Products, as a monotherapy treatment of patients with locally advanced and metastatic breast carcinoma with progression after prior therapy with an anthracycline, a taxane and capecitabine...

More... (http://www.medicalnewstoday.com/releases/225674.php)